Selection and antitumor activity of anti-Bcl-2 DNAzymes

Biochem Biophys Res Commun. 2016 Oct 21;479(3):544-550. doi: 10.1016/j.bbrc.2016.09.107. Epub 2016 Sep 22.

Abstract

Apoptosis pathway has become one of the important targets for therapeutic exploration for cancer therapy. The increased Bcl-2 protein level and phosphorylation is implicated in a decreased chemotherapeutic response in many cancers. BCL-2 inhibitors have been developed as direct inducers of apoptosis. However, resistance to BCL2 inhibitors has been emerging and thus considerable effort has been made to seek novel approaches to BCL2 suppression. In this report we describe an in vitro DNAzyme selection strategy resulting in molecules that are effective in suppressing expression of the target gene BCL-2 in vitro. A 3'-inverted modification was shown to significantly increase the DNAzyme stability in serum and the modified DNAzyme delivered by an osmotic pump chemosensitized human prostate cancer to Taxol in vivo. Thus this study provides an alternative strategy for potential BCL-2-targetd therapy.

Keywords: Apoptosis; Bcl-2; Chemoresistance; DNAzyme.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Cell Survival
  • DNA, Catalytic / pharmacology*
  • Female
  • Humans
  • Kinetics
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Oligonucleotides / genetics
  • Paclitaxel / pharmacology
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism

Substances

  • Antineoplastic Agents
  • DNA, Catalytic
  • Oligonucleotides
  • Proto-Oncogene Proteins c-bcl-2
  • Paclitaxel